Abstract
The symptoms of hypertrophic cardiomyopathy (HCM) result from a combination of high filling pressures (“backward” heart failure) and low cardiac output (“forward” heart failure). The mainstay of noninvasive testing in symptomatic patients with HCM is transthoracic echocardiography. The detection of concomitant coronary artery disease (CAD) as a cause of symptoms may be difficult by clinical assessment and exercise testing; cardiac computerized tomographic angiography (CTA) has emerged as perhaps the most useful noninvasive test for the assessment of potentially ischemic symptoms due to CAD. Cardiac catheterization is useful for documenting right-sided pressures and cardiac output; determining whether a left ventricular outflow tract (or midcavity) gradient is present at rest or with provocation; separating aortic valvular from subvalvular and supravalvular gradients; determining whether CAD is present; and excluding other pathologic causes of left ventricular thickening. Cardiopulmonary exercise testing provides quantification of functional capacity and distinguishes between cardiac and pulmonary contributions to symptoms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82(6):1995–2002. 617-782-6674.
Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293–8.
Kaple RK, Murphy RT, DiPaola LM, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85(5):1527–35, 35 e1–2.
Gupta RM, Weiner RB, Baggish AL, Fifer MA. Still a kid at heart: hypertrophic cardiomyopathy in the elderly. Circulation. 2011;124(7):857–63.
Ahn KT, Lee YD, Choi UL, et al. Flail subaortic membrane mimicking left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Cardiovasc Ultrasound. 2013;21(2):90–3.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.
O’Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation. 1987;76(6):1214–23.
Brockenbrough EC, Braunwald E, Morrow AG. A hemodynamic technic for the detection of hypertrophic subaortic stenosis. Circulation. 1961;23:189–94.
Balady GJ, Arena R, Sietsema K, et al. Clinician’s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191–225.
American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–77.
Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. Circulation. 2012;126(21):2465–72.
Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996;27(2):345–52.
Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36(3):864–70.
Kim JJ, Lee CW, Park SW, et al. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83(8):1220–3.
Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117(3):429–39.
Rothman RD, Baggish AL, O’Callaghan C, et al. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. Am J Cardiol. 2012;110(8):1169–74.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Fifer, M.A., Baggish, A.L. (2015). Assessment of Heart Failure: Invasive and Non-invasive Methods. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, London. https://doi.org/10.1007/978-1-4471-4956-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4956-9_7
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4955-2
Online ISBN: 978-1-4471-4956-9
eBook Packages: MedicineMedicine (R0)